Chugai Pharmaceutical Co., Ltd. · TSE:4519

Chugai Pharmaceutical — Q3 2016 Earnings Presentation

23 slides from Chugai Pharmaceutical's earnings presentation, Oct 25, 2016

  1. Slide 1: FY2016 3Q Consolidated Financial Overview (IFRS based)

    Slide 1: FY2016 3Q Consolidated Financial Overview (IFRS based)

    FY2016 3Q Consolidated Financial Overview (IFRS based) CHUGAI PHARMACEUTICAL CO., LTD. Vice President General Manager of Finance & Accounting Dept. Toshiaki Itagaki October 25, 2016

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    FY2016 3Q Consolidated Financial Overview Forward-Looking Statements This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the “Company”). These statements reflect the Company’s current analysis of existing information a

  3. Slide 3: 3Q Results Summary

    Slide 3: 3Q Results Summary

    FY2016 3Q Consolidated Financial Overview 3Q Results Summary  Revenues: 361.5billion yen (-6.3, -1.7% YoY) • Domestic sales excl. Tamiflu: increase due to steady growth of new products and mainstay products (+1.8, +0.7%) • Overseas sales: decrease due to impact of supply price reduction on Actemra

  4. Slide 4: IFRS and Core Results Jan-Sep

    Slide 4: IFRS and Core Results Jan-Sep

    FY2016 3Q Consolidated Financial Overview IFRS and Core Results Jan-Sep IFRS results Non-core items Core results (Billion JPY) 2016 2016 Intangible assets Others (Billions of JPY) Jan - Sep Jan - Sep Non-Core items Revenues 361.5 361.5 1. Intangible assets: Sales 347.5 347.5 Amortization of intangib

  5. Slide 5: Financial Overview Jan - Sep

    Slide 5: Financial Overview Jan - Sep

    FY2016 3Q Consolidated Financial Overview Year on Year (Core) Financial Overview Jan - Sep 2015 2016 (Billions of JPY) Jan - Sep Jan - Sep Growth vs. Revenues vs. Revenues (Billions of JPY) Revenues 367.8 361.5 -6.3 -1.7% Sales 353.3 347.5 -5.8 -1.6% Royalties and other operating income -0.5 excl. T

  6. Slide 6: Sales (excl. Tamiflu) Jan - Sep

    Slide 6: Sales (excl. Tamiflu) Jan - Sep

    FY2016 3Q Consolidated Financial Overview Year on Year Sales (excl. Tamiflu) Jan - Sep Sales by Disease Area, Sales by Products, Year on Year Comparisons Year on Year Changes *) Details of HER2 franchise (Billions of JPY) Herceptin (25.0) +0.9, +3.7% Kadcyla (6.1) +0.8, +15.1% Perjeta (8.6) +0.8, +1

  7. Slide 7: Tamiflu Sales Trends

    Slide 7: Tamiflu Sales Trends

    FY2016 3Q Consolidated Financial Overview Tamiflu Sales Trends Fiscal Term Sales Season (Billions of JPY) FY2011 FY2012 FY2013 FY2014 FY2015 FY2016 (from the second half of FY to Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Sep the first half of the nex

  8. Slide 8: Operating Profit Jan - Sep

    Slide 8: Operating Profit Jan - Sep

    FY2016 3Q Consolidated Financial Overview Year on Year (Core) Operating Profit Jan - Sep (Billion of JPY) 2015 2016 (Billions of JPY) Growth Jan - Sep Jan - Sep Revenues 367.8 361.5 -6.3 Gross profit from sales Cost of sales -177.7 -183.0 -5.3 Gross profit 190.1 178.6 -11.5 of which Sales 175.6 164.

  9. Slide 9: Financial Overview Jul – Sep

    Slide 9: Financial Overview Jul – Sep

    FY2016 3Q Consolidated Financial Overview Year on Year (Core) Financial Overview Jul – Sep 2015 2016 (Billions of JPY) (Billions of JPY) Jul - Sep Jul - Sep Growth vs. Revenues vs. Revenues Decrease in gross profit from sales -7.8 Revenues 127.6 114.0 -13.6 -10.7% Cost of sales ratio to sales worsen

  10. Slide 10: Financial Progress Jan – Sep

    Slide 10: Financial Progress Jan – Sep

    FY2016 3Q Consolidated Financial Overview vs. Forecast (Core) Financial Progress Jan – Sep Forecast Actual on Jan 28 2015 (Billions of JPY) 2016 2016 Progress Progress* Jan - Sep Jan - Dec Revenues 361.5 495.0 73.0% 73.7% Sales 347.5 475.4 73.1% 75.4% excl. Tamiflu 339.1 466.8 72.6% 75.3% Domestic 2

  11. Slide 11: Sales Progress (excl. Tamiflu) Jan – Sep

    Slide 11: Sales Progress (excl. Tamiflu) Jan – Sep

    FY2016 3Q Consolidated Financial Overview vs. Forecast (Core) Sales Progress (excl. Tamiflu) Jan – Sep Actual Forecast 2015 (Billions of JPY) 2016 2016 Progress Progress* Jan - Sep Jan - Dec Sales excl. Tamiflu 339.1 466.8 72.6% 75.3% Domestic 277.2 379.0 73.1% 72.9% Oncology 161.2 220.3 73.2% 72.7%

  12. Slide 12: Impact from Foreign Exchange

    Slide 12: Impact from Foreign Exchange

    FY2016 3Q Consolidated Financial Overview vs. Forecast (Core) Impact from Foreign Exchange FX impact Jan – Sep 2016 [Reference] (Billions of JPY) Historical exchange rate to the JPY (FX impact vs. Forecast) Forecast rate JPY 2016 EUR 2016 CHF 2015 EUR 2015 CHF -2.0 145 140 1EUR: 134JPY Revenues Sale

  13. Slide 13: Overview of Development Pipeline

    Slide 13: Overview of Development Pipeline

    Overview of Development Pipeline CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Business Assessment Dept. Shinichiro Iida October 25, 2016

  14. Slide 14: Oncology Field Projects under Development

    Slide 14: Oncology Field Projects under Development

    Overview of Development Pipeline Oncology Field Projects under Development (as of 25 Oct., 2016) Phase I Phase II Phase III Filed CKI27 / RG7304 RG435 / Avastin AF802 (RG7853) AF802 (RG7853) (Japan / overseas) - MPM / Alecensa (overseas) / Alecensa (EU) - solid tumors - NSCLC [1L] - NSCLC [post-criz

  15. Slide 15: Primary Field Projects under Development

    Slide 15: Primary Field Projects under Development

    Overview of Development Pipeline Primary Field Projects under Development (as of 25 Oct., 2016) Phase I Phase II Phase III Filed ED-71 / Edirol (China) Bone & Joint - osteoporosis EOS789 Renal - hyperphosphatemia MRA / Actemra - large-vessel vasculitis - giant cell arteritis Autoimmune (overseas) -

  16. Slide 16: Development Status

    Slide 16: Development Status

    Overview of Development Pipeline Development Status In- GC33 / codrituzumab house Hepatocellular carcinoma Started P1 in August 2016 (in combination with RG7446) In- ERY974 house Solid tumor Started overseas P1 in August 2016 In- RG6078 (IDO inhibitor) licensed Solid tumor Started P1 in September 20

  17. Slide 17: Other Progress (1/2)

    Slide 17: Other Progress (1/2)

    Overview of Development Pipeline Other Progress (1/2) In- Xeloda® licensed Adjuvant therapy for rectal cancer (additional indication) Approved in August 2016 (public knowledge-based application) In- Actemra® house Rheumatoid arthritis (weekly dose) Filed in August 2016 In- CIM331 / nemolizumab house

  18. Slide 18: Other Progress (2/2)

    Slide 18: Other Progress (2/2)

    Overview of Development Pipeline Other Progress (2/2) Breakthrough therapy designation from US FDA In- AF802 / Alecensa® house 1st line treatment of ALK positive non-small cell lung cancer In- MRA / Actemra® house Giant cell arteritis Discontinuation of development In- GA101 / obinutuzumab licensed

  19. Slide 19: Data Presentation / Results of Clinical Trials

    Slide 19: Data Presentation / Results of Clinical Trials

    Overview of Development Pipeline Data Presentation / Results of Clinical Trials In- RG7446 / atezolizumab licensed • Global P3 (OAK study) for non-small cell lung cancer met its Primary endpoint in September 2016 • Detailed data of OAK study was presented at the European Society for Medical Oncology

  20. Slide 20: Projected Submissions (Post PoC NMEs and Products)

    Slide 20: Projected Submissions (Post PoC NMEs and Products)

    Overview of Development Pipeline Projected Submissions (Post PoC NMEs and Products) Filed ALECENSA (AF802/RG7853) NME line extension NSCLC in-house [post-crizotinib] (EU) emicizumab in-licensed (ACE910/RG6013) Hemophilia A NHL: non-Hodgkin’s lymphoma (non-inhibitor) MPM: malignant pleural mesothelio

  21. Slide 21: Emicizumab (ACE910) Pediatric inhibitor Phase III: HAVEN 2

    Slide 21: Emicizumab (ACE910) Pediatric inhibitor Phase III: HAVEN 2

    Overview of Development Pipeline Emicizumab (ACE910) Pediatric inhibitor Phase lll: HAVEN 2 Pediatric inhibitor patients receiving bypassing agents <12 years old1, N=40 Episodic or prophylactic bypass (patients on episodic treatment and scheduled treatment) emicizumab 1.5 mg/kg/week2 1 With allowanc

  22. Slide 22: Emicizumab (ACE910) Non-inhibitor Phase III: HAVEN 3

    Slide 22: Emicizumab (ACE910) Non-inhibitor Phase III: HAVEN 3

    Overview of Development Pipeline Emicizumab (ACE910) Non-inhibitor Phase lll: HAVEN 3 Non-inhibitor patients receiving FVIII agents ≥12 years old, N=145 Episodic FVIII Prophylaxis FVIII (patients on episodic treatment) (patients on scheduled treatment) A) emicizumab B) emicizumab C) D) emicizumab 1.

  23. Slide 23: Contacts: Corporate Communications Dept.

    Slide 23: Contacts: Corporate Communications Dept.

    Contacts: Corporate Communications Dept. Media Relations Group Tel: +81 (0)3-3273-0881 Fax: +81 (0)3-3281-6607 e-mail: pr@chugai-pharm.co.jp Koki Harada, Hiroshi Araki, Sachiyo Yoshimura, Chisato Miyoshi, Yayoi Yamada Investor Relations Group Tel: +81 (0)3-3273-0554 Fax: +81 (0)3-3281-6607 e-mail: i

Source: Internet Archive copy of chugai-pharm.co.jp

More decks from Chugai Pharmaceutical Co., Ltd.

All 107 Chugai Pharmaceutical decks